| scholarly article | Q13442814 |
| P50 | author | Dominique Campion | Q32424891 |
| Didier Hannequin | Q32424966 | ||
| Frédéric Checler | Q38321085 | ||
| P2093 | author name string | Catherine Thomas-Antérion | |
| Martine Vercelletto | |||
| Anne Vital | |||
| Annie Laquerrière | |||
| Florence Pasquier | |||
| Thierry Frebourg | |||
| Christophe Verny | |||
| Lucie Guyant-Maréchal | |||
| Lucie Cabrejo | |||
| Franck Letournel | |||
| François De la Fournière | |||
| P433 | issue | Pt 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| P304 | page(s) | 2966-2976 | |
| P577 | publication date | 2006-09-07 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Phenotype associated with APP duplication in five families | |
| P478 | volume | 129 |
| Q92188317 | A Longitudinal Study of Epileptic Seizures in Alzheimer's Disease |
| Q26798983 | A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome |
| Q41817650 | A perfect storm: Converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation |
| Q57384500 | A practical approach to diagnosing adult onset leukodystrophies |
| Q55315340 | A systematic approach for identifying shared mechanisms in epilepsy and its comorbidities |
| Q26785905 | A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences |
| Q40991422 | ALS/FTD-associated FUS activates GSK-3β to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations. |
| Q36028971 | APL-1, the Alzheimer's Amyloid precursor protein in Caenorhabditis elegans, modulates multiple metabolic pathways throughout development |
| Q48327983 | APLP1 and APLP2, members of the APP family of proteins, behave similarly to APP in that they associate with NMDA receptors and enhance NMDA receptor surface expression |
| Q39011999 | APP Mutations in Cerebral Amyloid Angiopathy with or without Cortical Calcifications: Report of Three Families and a Literature Review |
| Q36226613 | APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage |
| Q37293809 | Abeta aggregation and possible implications in Alzheimer's disease pathogenesis |
| Q36478423 | Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis |
| Q34219814 | Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy |
| Q41908070 | Aging and excitotoxic stress exacerbate neural circuit reorganization in amyloid precursor protein intracellular domain transgenic mice |
| Q38129324 | Aging and intellectual disability: insights from mouse models of Down syndrome |
| Q33586813 | Altered Kv2.1 functioning promotes increased excitability in hippocampal neurons of an Alzheimer's disease mouse model. |
| Q22251261 | Alzheimer's disease as homeostatic responses to age-related myelin breakdown |
| Q37422018 | Alzheimer-related protein APL-1 modulates lifespan through heterochronic gene regulation in Caenorhabditis elegans. |
| Q38006665 | Amyloid and Alzheimer's disease: inside and out. |
| Q36771307 | Amyloid precursor protein controls cholesterol turnover needed for neuronal activity |
| Q30489361 | Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides |
| Q24622558 | Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks |
| Q26866265 | Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease |
| Q36739111 | An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome |
| Q34442793 | An Intron 7 Polymorphism in APP Affects the Age of Onset of Dementia in Down Syndrome |
| Q92106898 | Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications |
| Q42179622 | Association of Tag SNPs and Rare CNVs of the MIR155HG/miR-155 Gene with Epilepsy in the Chinese Han Population |
| Q38259551 | Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes |
| Q37993451 | Aβ toxicity in Alzheimer's disease |
| Q26851244 | Caenorhabditis elegans as a model organism to study APP function |
| Q47965740 | Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. |
| Q38174619 | Clinical, biological, and imaging features of monogenic Alzheimer's Disease |
| Q37759873 | Cognitive deficits and associated neurological complications in individuals with Down's syndrome |
| Q27010627 | Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system |
| Q33303453 | Copy number variants and common disorders: filling the gaps and exploring complexity in genome-wide association studies |
| Q33871345 | Current status on Alzheimer disease molecular genetics: from past, to present, to future |
| Q30412535 | DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease |
| Q104459061 | Delta-secretase triggers Alzheimer's disease pathologies in wild-type hAPP/hMAPT double transgenic mice |
| Q91410950 | Dementia in Down syndrome: unique insights for Alzheimer disease research |
| Q38865366 | Dementia in Down's syndrome |
| Q26777254 | Dissecting Alzheimer disease in Down syndrome using mouse models |
| Q42601869 | Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP. |
| Q36681400 | Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21. |
| Q36150463 | Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease |
| Q36854788 | Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series |
| Q58785711 | Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease |
| Q64237829 | Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura |
| Q35175125 | Early onset of hypersynchronous network activity and expression of a marker of chronic seizures in the Tg2576 mouse model of Alzheimer's disease |
| Q37719047 | Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Aβ Antibody and by mGluR5 Blockade. |
| Q37606162 | Early-onset dementias: diagnostic and etiological considerations |
| Q38021307 | Early-onset familial Alzheimer's disease (EOFAD). |
| Q33616746 | Epilepsy and cognitive impairments in Alzheimer disease |
| Q22305926 | Etiologies of epilepsy: a comprehensive review |
| Q29301019 | Expanded high-resolution genetic study of 109 Swedish families with Alzheimer's disease |
| Q93181542 | Facilitation of glutamate, but not GABA, release in Familial Alzheimer's APP mutant Knock-in rats with increased β-cleavage of APP |
| Q37542635 | Genetic animal models of cerebral vasculopathies |
| Q37633601 | Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease |
| Q46300376 | Genomic disorders 20 years on-mechanisms for clinical manifestations |
| Q34634523 | Implications of copy number variation in people with chromosomal abnormalities: potential for greater variation in copy number state may contribute to variability of phenotype |
| Q37940158 | Implications of gene copy-number variation in health and diseases. |
| Q39328473 | Incidence and impact of subclinical epileptiform activity in Alzheimer's disease |
| Q24603560 | Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model |
| Q61855138 | Insights into genetics, human biology and disease gleaned from family based genomic studies |
| Q64041297 | Insights into genetics, human biology and disease gleaned from family based genomic studies |
| Q36528274 | Insulin receptor signaling mediates APP processing and β-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease |
| Q29615626 | Intracellular amyloid-beta in Alzheimer's disease |
| Q26745369 | Intracerebral haemorrhage in Down syndrome: protected or predisposed? |
| Q57814457 | Large APP locus duplication in a sporadic case of cerebral haemorrhage |
| Q34462326 | Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice |
| Q53316377 | Linkage analysis of autopsy-confirmed familial Alzheimer disease supports an Alzheimer disease locus in 8q24. |
| Q43994098 | Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease |
| Q37855656 | Mechanisms of neural and behavioral dysfunction in Alzheimer's disease |
| Q64270312 | Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease |
| Q33889532 | Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS |
| Q37209771 | Molecular genetics of Alzheimer's disease: an update |
| Q37964886 | Mouse models of Alzheimer's disease |
| Q38993138 | Mouse-based genetic modeling and analysis of Down syndrome |
| Q39112723 | Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient |
| Q33705813 | Network Excitability Dysfunction in Alzheimer's Disease: Insights from In Vitro and In Vivo Models |
| Q38796950 | Network abnormalities and interneuron dysfunction in Alzheimer disease |
| Q50463961 | Neurons Derived from Induced Pluripotent Stem Cells of Patients with Down Syndrome Reproduce Early Stages of Alzheimer's Disease Type Pathology in vitro. |
| Q39196646 | Normalization of Overexpressed α-Synuclein Causing Parkinson's Disease By a Moderate Gene Silencing With RNA Interference |
| Q33831242 | Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease |
| Q36974448 | Pan-neuronal expression of APL-1, an APP-related protein, disrupts olfactory, gustatory, and touch plasticity in Caenorhabditis elegans |
| Q60721200 | Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease |
| Q38218353 | Potential Similarities in Temporal Lobe Epilepsy and Alzheimer’s Disease: From Clinic to Pathology |
| Q37723422 | Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease |
| Q33608732 | Regulation of amyloid precursor protein processing by the Beclin 1 complex |
| Q37957630 | Role of APP for dendritic spine formation and stability |
| Q34070798 | Seizures and epilepsy in Alzheimer's disease |
| Q30577633 | Seizures and epileptiform activity in the early stages of Alzheimer disease |
| Q30575767 | Seizures in Alzheimer disease: clinical and epidemiological data |
| Q37583653 | Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms |
| Q102369181 | TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease |
| Q27334314 | Tau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer's-Like Pathological Features in Mice |
| Q55385303 | Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models. |
| Q34165340 | The diagnosis of young-onset dementia. |
| Q34123651 | The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. |
| Q36678673 | The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida |
| Q38094984 | The senescence hypothesis of disease progression in Alzheimer disease: an integrated matrix of disease pathways for FAD and SAD. |
| Q41887222 | The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer's disease |
| Q28082768 | Three dimensions of the amyloid hypothesis: time, space and 'wingmen' |
| Q46617670 | Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice |
| Q39450295 | Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before: ApoE, APP transcription and AD: Hypothesised mechanisms and existing knowledge gaps |
| Q38968481 | Treatment of epilepsy in patients with Alzheimer's disease |
| Q41428294 | Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged AβPP/PS1 double transgenic mice |
| Q37515518 | Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system |
| Q47431150 | Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. |
| Q47706142 | What goes up must come down: homeostatic synaptic plasticity strategies in neurological disease |
| Q53296862 | [Hereditary Alzheimer's disease with amyloid angiopathy caused by amyloid precursor protein locus]. |
Search more.